The appearance of multidrug-resistant (MDR) proteins or the acquisition of a defective apoptotic programme are major drawbacks in the treatment of cancers since both induce a resistance to classical chemotherapy. However, a link between the two mechanisms has not, as yet, been clearly established. In this study, HL-60 cells cultured in the continual presence of a sub-lethal dose of doxorubicin (dox; HL-60/Dox) were used as a model to study acquired chemoresistance. During the induction of chemoresistance, the appearance of a functional P-glycoprotein (P-gp), in addition to the expression of anti-apoptotic Bcl-2, Bcl-XL and pro-apoptotic Bax proteins was assessed. Parental cells which are sensitive to dox, have no P-gp activity and express Bcl-2 and Bax. After 4 weeks of treatment, a functional P-gp was detected in HL-60/Dox cells. In addition, the synthesis of Bcl-2 appeared to be replaced by Bcl-XL while that of Bax remained unchanged. These cells were also resistant to apoptosis induced by both P-gp and non-P-gp substrates. This inability to induce apoptosis could have resulted from the induction of the expression of the inhibitor of apoptosis protein (XIAP). Our data show that acquired chemoresistance could involve a parallel induction of P-gp and an impairment of the apoptotic pathway. Leukemia (2001) 15, 1377-1387.
Introduction
The majority of anti-cancer drugs used in chemotherapy eradicate tumoral cells by inducing apoptosis. 1 Resistance to chemotherapy is an important impediment constraining the successful treatment of patients. 2 Multidrug resistance (MDR) may be either an inherent resistance to a broad spectrum of chemotherapeutic drugs (intrinsic resistance) or 'acquired' (ie the mechanism of resistance may be procured during the course of treatment), which in both cases result in acutely resistant forms of cancer at relapse. 3 The molecular steps implicated in the induction of this resistance remain unknown. Many reports have demonstrated that the overexpression of a variety of membrane (eg P-glycoprotein (P-gp) or multidrug-resistant protein (mrp)) or intracellular proteins (eg lung-resistant protein) is responsible for the reduced intracellular accumulation of cytotoxic drugs thereby preventing cytotoxicity. [4] [5] [6] [7] [8] [9] These proteins constitute the first or proximal mechanism of MDR. The sequence and domain organization of P-gp is typical of the ATP-binding cassette superfamily of active transporters. 10 A functional P-gp causes the active transport of cytotoxic drugs out of the cells, against a concentration gradient, resulting in a reduction in the intracellular accumulation of drugs and thereby increasing drug resistance. 10 However, a similar phenotype may be observed in the absence of MDR proteins [11] [12] [13] implicating other proteins in a pleiotropic drug resistance. The BCL-2 family of proteins constitutes a critical intracellular checkpoint within this distal common cell death pathway. 14 The ratio of the BCL-2 family pro-to anti-apoptotic proteins in the cell, will determine the susceptibility of the cell to a variety of apoptotic signals. 15 The level of expression of Bcl-2-related proteins can be modulated during tumorigenesis or during chemotherapy, implying that these proteins may play an important role in tumor progression and/or chemoresistance. 16 Bcl-2 and Bcl-XL, both pro-survival proteins are thought to inhibit chemotherapyinduced apoptosis, at least in part, by repressing drug-induced caspase activation. 17 Data available have shown that the main mechanism responsible for initiating the executioner phase of programmed cell death, is the release of cytochrome c (cyto c) from the mitochondria. [18] [19] [20] The mechanism of activation of effector caspases in the Bcl-2-sensitive pathway implicates the potential role of mitochondria. 15, 21, 22 Overexpression of anti-apoptotic Bcl-2 and Bcl-XL proteins have been associated with a poor response to chemotherapy in acute myeloid leukemia (AML), 23 in multiple myeloma 24 and in mammary tumors. 13 In addition, numerous reports have documented an increased expression of Bcl-XL in cells overexpressing Pgp 3, [25] [26] [27] [28] suggesting a co-existence between the proximal and the distal mechanisms of drug resistance.
Another level of control of apoptosis involves the inhibitor of apoptosis (IAP) family of proteins. This family of genes, to date six proteins (viz. NAIP, c-IAP1, c-IAP2, survivin, XIAP and BRUCE), has an evolutionary conserved role in suppressing programmed cell death in diverse species. 29 Recent studies have shown that IAPs regulate apoptosis by inhibiting caspases directly and in particular caspase-3, -7, and -9. 30, 31 These observations are consistent with reports that IAPs inhibit apoptosis downstream of pro-apoptotic members of the BCL-2 family and cyto c release. 32 We show here that induction of a MDR phenotype, with procurement of P-gp, is accompanied by an acquisition of an inhibition to apoptosis concomitant to a change in the expression of anti-apoptotic molecules and to an inhibition of caspase-3 activation due to the synthesis of XIAP.
Materials and methods

Materials
Unless otherwise specified, all reagents used in this study were from Sigma (St Quentin Fallavier, France). Commercial antibodies used in Western blots were anti-actin (2 g/ml; Boehringer-Mannheim, Mannheim, Germany), anti-Bax (1 g/ml; Upstate Laboratories, Lake Placid, NY, USA), antiBcl-2 (1 g/ml; Dako, Trappes, France), anti-Bcl-XL (1 g/ml; Transduction Lab, Le Pont de Claix, France), anti-XIAP (1 g/ml; R&D Systems, Oxon, UK), anti-cyto c (1 g/ml; Pharmingen, Heidelberg, Germany), anti-caspase-3 (1 g/ml; Transduction Lab) and anti-Mcl-1 (4 g/ml; Dako). Doxorubicin (dox) was obtained from Dakota Pharmaceutics (France). All cell culture materials were obtained from Life Tech (Cergy Pontoise, France). The fluorogenic peptides Ac-DEVD-AMC, Ac-LEHD-AMC and Bz-VGR-AMC were obtained from BACHEM (Switzerland).
Cell culture
K562/ADR cells (dox-resistant sub-line cultured in the presence of 1 m dox) were kindly provided by Dr S Chevillard (Institut Curie, Paris, France) and were used as a positive control in the P-gp assay. HL-60/ADR cells (dox-resistant sub-line cultured in the presence of 200 ng/ml dox) originally derived in the laboratories at Melvin Center (Kansas City, KS, USA) were kindly provided by Dr H Broxterman (Free Univ. Hosp., Amsterdam, The Netherlands). HL60/ADR cells were used as a positive control for the MRP study. To isolate the HL-60/Dox cells, promyelocytic leukemic HL-60 cells were seeded at a density of 10 7 cells/100 mm dish and cultured in the continual presence of 4 ng/ml dox. More than 80% of the cells died within the first 14 days. The remaining cells started to proliferate after 21 days in culture to give the HL-60/Dox cells. The induction of chemoresistance was performed three times (HL-60/Dox 1, HL-60/Dox2 and HL-60/Dox3) and gave similar results. The results reported in this study were mainly obtained with HL-60/Dox1 cells. The media were changed every 2-3 days. All cell lines were cultured in RPMI-1640 supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 g/ml streptomycin and 2 mm glutamine. All cultures were incubated at 37°C in an atmosphere of 5% CO 2 -95% air.
Flow cytometry
The labeling of P-gp and mrp were performed as described in Ref. 33 . Briefly, the cells were fixed with 1% formaldehyde for 15 min at room temperature, then permeabilized in methanol for 10 min at −20°C. Cells (1.5 × 10 5 ) were incubated for 90 min at 4°C in 100 l PBS/1% BSA and 10% goat serum containing the monoclonal antibodies against P-gp (UIC2; Immunotech, Beckman Coulter, France or 4E3; Dako), against mrp (mrp-m6, Genzyme, France) or the isotype matched IgGs. After washing with PBS/1% BSA, the cells were incubated with FITC-labeled antibodies for 1 h at 4°C. Fluorescence was analyzed in a FACSCAN flow cytometer (Pharmingen). For each sample, 5000 events were collected. Protein values were expressed as ratio of arithmetic mean fluorescence of MoAb/isotypic control.
Functional test for P-gp and mrp
The functional analyses were done according to the recommendations set out by Marie et al. 33 Briefly, for P-gp the cells (1. 
Western blots and quantification
Cells were homogenized vol:vol in RIPA buffer (PBS containing 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 1 nm Navanadate and 1 tablet complete cocktail inhibitor (Boehringer Mannheim)). After several passages in a 2 ml glass Potter homogenizer, the homogenates were centrifuged at 4°C at 13 000 g for 30 min. The resulting supernatants were assayed for protein concentration (Bio-Rad, Ivry Sur Seine, France) prior to analysis under reducing conditions in 15% SDS-PAGE. Western blots were performed using standard protocol. Antibodies bound to Immobilon-P (Millipore, St Quentin Yvelines, France) were detected by ECL (Amersham, Orsay, France) using a second antibody coupled to peroxidase. The amount of immunoreactive proteins was quantified using IPLab Gel Program (Signal Analytics, Vienna, USA) after scanning with an Imager (Quantum Appligene, Illkirch, France).
Laser confocal microscopy
For confocal analysis, the cells were fixed with 4% paraformaldehyde-0.15% picric acid in PBS for 15 min. After a 30 min saturation with 3% BSA-PBS, the cells were incubated with anti-F1-ATPase (1/500; a gift from Prof J Lunardi, URA-CNRS 1130, Grenoble, France) for 1 h then washed and incubated overnight at 4°C with either Bcl-2 (same dilution as in immunoblots) or Bcl-XL (0.5 g/ml; Transduction Lab). After extensive washing, the sections were incubated with each secondary antibodies for 1 h (anti-mouse IgG coupled to rhodamine then anti-rabbit IgG coupled to fluorescein). All incubations were done at room temperature unless stated otherwise. Images were visualized using a Leica TCS NT microscope with a 63 × 1.3 NA Fluotar objective (Leica, France).
RT-PCR
Total RNA was prepared using a SV-Total RNA isolation system (Promega, Charbonnieres, France). The cDNA was prepared from 1 g total RNA using reverse transcriptase (SuperScript; Life Tech). The oligonucleotide primers used for the amplification of human Bcl-2 were sense 5Ј-ggacaa catcgccctgtg and antisense 5Ј-tcagaagtctctgtcggtcct which gave an amplified fragment of 150 bp; of human Bax were sense 5Ј-ccgagtggcagctgacat and antisense 5Ј-cacccgca gggtttcatc which gave an amplified fragment of 230 bp; of human Bcl-XL were sense 5Ј-agggccaggaacgcttcaac and antisense 5Ј-gcccaagaggaccaccgttacc which gave an amplified fragment of 181 bp and of human ␤ 2 -microglobulin were sense 5Ј-ttcacccccactgaaaaagatga and antisense 5Ј-ggcatcttcaaacctccatgatg which gave an amplified fragment of 120 bp. All primers were synthesized by Genosys-Sigma (Cambridge, UK). For the amplification 40 ng cDNA was amplified in a final volume of 30 l using 1 U Taq polymerase (Life Tech). Thirty amplification cycles, consisting of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s were performed. Ten l amplified products were analyzed in a 2% agarose gel. The bands were quantified as described for Western blots.
Quantification of lactate dehydrogenase (LDH) activity
The release of LDH by the cells was quantified using a CytoTox 96 non-radioactive cytotoxicity assay (Promega) after STS treatment. Twenty l cell conditioned media were assayed in 100 l according to the manufacturer's instructions and read at 490 nm every 5 min over 1 h.
Preparation of cytosolic extracts and analysis of DEVDase activity
The cytosolic extracts were prepared as follows: briefly, cells were collected and centrifuged at 800 g for 10 min at 4°C. The cell pellets were washed with ice-cold PBS then resuspended in vol/vol CEB (250 mm sucrose, 50 mm Hepes pH 7.4, 50 mm KCI, 2 mm MgCl 2 , 1 mm DTT, 10 m cytochalasin B, 1 mm EDTA, 1 mM EGTA and 1 tablet complete cocktail inhibitor). Cells were allowed to swell for 30 min on ice. The cells were then homogenized with 30 strokes in a 2 ml glass Potter homogenizer. The homogenates were centrifuged at 800 g for 10 min at 4°C and then the resulting supernatants centrifuged for a further 15 min at 13000 g 4°C to obtain the mitochondrial pellets (P13). These supernatants were then centrifuged at 100 000 g for 30 min in an airfuge (Beckman Instruments, France) and the resulting cytosolic fraction was further referred to as the S100. DEVDase, LEHDase or VGRase activities were measured as previously described. 34 
DNA ladder assay
The DNA was prepared as described in Juin et al 34 then separated in a 2% agarose gel and stained with ethidium bromide to visualize DNA.
Statistical analysis
Statistical analyses were done using the Instat 2.00 programme. The results, unless otherwise stated, are expressed as the mean ± s.e.m.
Results
Analysis of a functional P-gp
Analysis of the expression and function of P-gp was done by flow cytometry, every week over the time of treatment until the establishment of the dox-resistant HL-60/Dox cells. P-gp was visualized with two separate monoclonal antibodies, UIC2 and 4E3 as described in Materials and methods. Prior to 4 weeks of treatment, none of the proteins characterizing a MDR phenotype were expressed in HL-60 cells (data not shown). The results presented in Figure 1a are characteristic of the data obtained after 4 weeks of treatment. In parental HL-60 cells all the peaks obtained with UIC2, 4E3 and isotype mouse IgG (used as a control) superimposed illustrating the absence of specific reactivity against P-gp. In contrast, with K562/ADR (positive control) or with HL-60/Dox cells a displacement of the second peak corresponding to anti-P-gp labeled cells was observed (the first peak represented the isotypic control).
To determine whether the P-gp expressed by HL-60/Dox
Leukemia cells was functional, an analysis of the incorporation and efflux of Rh-123 was done. The results showed that more Rh-123 was incorporated into HL-60 cells than into K562/ADR or HL-60/Dox cells, as depicted by a displacement of the peak of Rh-123 to the right (Figure 1b) . The presence of verapamil, a P-gp blocker, had no effect on the displacement of the peak in parental HL-60 cells, however, in the positive control K562/ADR and in HL-60/Dox cells, verapamil increased the displacement of the peak to the right suggesting an inhibitory action on a functional P-gp (Figure 1b) . The phenomenon was reinforced by the efflux analysis (Figure 1c) . In parental HL-60 cells, the Rh-123 peak was neither decreased nor displaced in the presence of verapamil suggesting the absence of functional P-gp. In contrast, in K562/ADR and HL-60/Dox cells, all Rh-123 was exported out of the cells, however, the addition of verapamil blocked this export demonstrating its inhibitory action on the function of P-gp (Figure 1c) . The presence of a functional mrp was determined as described in the Materials and methods section. The antibody mrp-m6, directed against mrp revealed no specific binding in HL-60/Dox cells and the functional assay using calcein and probenecid manifested no functional activity (see Figure 1d ) suggesting that no functional mrp was present on these cells.
Induction of apoptosis in HL-60 cells by dox and Ara-C
To determine the specificity of the chemoresistance of HL-60/Dox cells both the parental and dox-resistant HL-60/Dox cells were treated with dox, and with cytosine arabinoside (Ara-C; an anti-metabolic drug also used in the chemotherapeutic treatment of leukemias) but which is not a substrate for P-gp, in the absence or in the presence of 10 m verapamil. The cells were either lysed in RIPA buffer or the DNA was purified and separated in a 2% agarose gel. The results presented in Figure 2a and b show that treatment with dox produced no cleavage Ac-LEHD-AMC or Ac-DEVD-AMC in HL-60/Dox cells whether cultured in the absence or in the presence of verapamil; unlike the results obtained with the parental HL-60 cells which contained measurable amounts of LEHDase and DEVDase activity suggesting an induction of apoptosis in these cells. These data were confirmed in DNA agarose gels (Figure 2c ) which indicated DNA fragmentation, characteristic of apoptotic cells, in HL-60 cells treated with dox both in the absence or in the presence of verapamil, however, no DNA fragmentation was observed in HL-60/Dox cells reinforcing the fact that HL-60/Dox cells possessed a functional P-gp.
The addition of the non P-gp substrate Ara-C to the cultures resulted in the production of LEHDase and DEVDase activity in HL-60 cells, however, in HL-60/Dox cells no measurable amounts of either LEHD or DEVD cleavage were detected (Figure 2a and b) . Analysis of the nuclei showed the presence of DNA fragmentation in HL-60 but not in HL-60/Dox cells ( Figure 2c) . As expected the presence of verapamil did not alter the effect of Ara-C.
HL-60/Dox cells were resistant to apoptosis by non-P-gp substrate
P-gp has been suggested to protect cells against all apoptotic signals that are caspase-dependent. 35 To determine whether the HL-60/Dox cells were resistant to apoptosis induced by The presence of a functional P-gp in HL-60/Dox cells. HL-60 and HL-60/Dox cells were regularly tested for the presence of a functional P-gp using K526/ADR cells as a positive control as described in Materials and methods. (a) The presence of P-gp was determined in HL-60, K562/ADR and HL-60/Dox cells using antibodies 4E3 (solid line) and UIC2 (broken line) raised against P-gp. The peak (gray) represents the data obtained with the control isotypic IgG. The functionality of the P-gp was assessed by incubating the cells in the presence of Rh-123 (−V) or in the presence of Rh-123 plus verapamil a blocker of P-gp (+V) in an incorporation test (b) or in an efflux test (c) as described in Materials and methods. (d) The absence of mrp was determined using the mrp-m6 antibody (clear graph) vs a control isotypic IgG (shaded graph). The functionality of mrp was determined using calcein in the absence or in the presence of probenecid. These results are representative of seven separate experiments.
other diverse non-P-gp substrates, the cells were cultured in the presence of an inhibitor of protein kinases, staurosporine (STS), which is a potent inducer of apoptosis in several cell types including HL-60 cells. STS was added at 5 g/ml in the presence or in the absence of 10 m verapamil. The cells and the cell conditioned media were collected at 1 h intervals. As shown in Figure 3a , DNA fragmentation was present in parental HL-60 cells as early as 3 h after treatment with STS. However, no DNA fragmentation was detected in HL-60/Dox cells treated with STS in the absence or in the presence of verapamil, at any of the times assayed. This result suggests that the inhibition of apoptosis in these cells was not exclusive to the presence of P-gp since the presence of verapamil did not reverse the inhibition to apoptosis.
The cell conditioned media were assayed for the release of LDH by the cells during STS treatment. The data presented in Figure 3b depict a continual release of LDH by HL-60 cells. In contrast, no leakage of LDH was observed in HL-60/Dox Induction of apoptosis in HL-60 cells and HL-60/Dox by dox and Ara-C. HL-60 (hatched) and HL-60/Dox (grey) cells were cultured in the absence or in the presence of 10 m verapamil (Vera) with or without 200 ng/ml dox for 6 h or 10 m Ara-C for 4 h. The cells were then collected, lysed and the caspase activity analyzed. About 20 g whole cell lysates were assayed for specific DEVDase activity (a) or LEHDase activity (b). Alternatively, the DNA was purified and separated on agarose gels (c). The results presented in a and b are representative of an experiment repeated three times and are expressed as the mean ± s.e.m. of three separate points from a single experiment. The data in c are representative gels from three independent experiments. cell cultures suggesting that cell death other than by apoptosis had not occurred and that these cells were still viable after STS treatment.
The DEVDase activity which would correspond to effector caspase activity (viz. caspase-3) was determined in these cell extracts. As shown in Figure 3c DEVDase activity was detected in HL-60 cells as early as 1 h after the addition of STS and peaked after 4 h. No DEVDase activity was observed in HL-60/Dox cells at any of the times assayed either in the presence or in the absence of verapamil confirming the data obtained from the the DNA gels.
HL-60 and HL-60/Dox cells were also subjected to 1 min irradiation with UV-AB and then at different times the cells Leukemia were collected and the DEVDase activity and the nuclear analyzed. As depicted in Figure 3d , 24 h after treatment with UV-AB, the DEVDase activity was augmented in HL-60 cells 9.82-fold suggesting an activation of caspase-3 in these cells. In contrast, no detectable increase in DEVDase activity was noted in HL-60/Dox cells. Even at 48 h post-UV treatment no apoptotic nuclei were detected in HL-60/Dox cells.
Expression of the members of the BCL-2 family
We analyzed the expression of members of the Bcl-2 family as an increase in anti-apoptotic Bcl-2, Bcl-XL, and Mcl-1 has Induction of apoptosis by non-P-gp substrates. Apoptosis was induced in HL-60 and HL-60/Dox cells with 5 g/ml STS in the presence or in the absence of verapamil. At different times the cells and the cell conditioned media were collected and (a) the DNA was purified and separated in 2% agarose gels as described in Materials and methods. (b) The cell conditioned media from the cultures were assayed for LDH activity. (c) The cells were lysed and the extracts were assayed for the specific DEVDase activity. (d) HL-60 and HL-60/Dox cells were subjected to 1 min of UV-AB and then incubated for 24 h. The specific DEVDase activity was then measured in control (hatched) and UV-AB-treated (gray) cells. The data presented in a are representative of an experiment repeated three times. The data in b, c and d are expressed as the mean ± s.e.m. of three separate points from a single experiment repeated three times. been shown to be responsible for resistance to apoptosis under numerous physiopathological situations. 16, 36 Parental HL-60 cells expressed both anti-apoptotic Bcl-2 and proapoptotic Bax but not anti-apoptotic Bcl-XL (Figure 4a ). Analysis of the expression of the BCL-2 family during the induction of chemoresistance showed no change in the level of expression of these proteins. However, after 4 weeks, which corresponded to the renascence of the HL-60/Dox cells and the expression of P-gp, Bcl-2 was no longer detected in these cells and instead expressed the anti-apoptotic protein Bcl-XL. Western blotting revealed the presence of Mcl-1 in HL-60 cells which was augmented about five-fold in HL-60/Dox cells (Figure 4a ). On the other hand, the expression of the proapoptotic protein Bax remained unchanged (Figure 4a) .
To determine whether this switch in the expression from Bcl-2 to Bcl-XL was due to transcriptional alterations or to a change in protein turnover, RT-PCRs were done. The mRNAs encoding Bcl-2 and Bax were detected in HL-60 while only that of Bcl-XL and Bax were observed in HL-60/Dox cells (Figure 4b ). The profile of the mRNA corresponded to that of the protein suggesting that the switch in the expression from Bcl-2 to Bcl-XL in HL-60/Dox was due to modifications arising at the transcriptional level.
Intracellular localization of Bax, Bcl-2 and Bcl-XL
Numerous studies have shown that members of the Bcl-2 family control apoptosis at the level of the mitochondria. 15, 16 Laser confocal microscopy was done on HL-60 and HL-60/Dox cells to determine the intracellular localisation of Bcl-2 and Bcl-XL. A double labeling of the mitochondria using an antibody specific for mitochondrial protein, F1-ATPase was performed in conjunction with either anti-Bcl-2 or anti-Bcl-XL antibodies. The results in Figure 5a show a mitochondrial staining with anti-Bcl-2 in HL-60 cells only. In HL-60/Dox cells we observed both a mitochondrial and cytoplasmic a Figure 5 Intracellular localization of Bcl-XL, Bax and Bcl-2 in HL-60 and HL-60/Dox cells. (a) HL-60 and HL-60/Dox cells were fixed then immunocytochemically labeled with anti-F1-ATPase (mitochondria) and anti-Bcl-2 or anti-Bcl-XL. The immunostaining was visualized by laser confocal microscopy then analyzed using Adobe Photoshop 5.0. Cell fractionation was done on HL-60 and HL-60/Dox cells as described in Materials and methods and the P13 and S100 fractions were analyzed by Western blot. (b) Fifty g protein was loaded on to the gel and the presence of Bcl-XL, Bax and Bcl-2 was detected. The presence of actin was used as an internal control, to quantify the proteins in the S100 and the presence of COX-IV (mitochondria) was used to attest the quality of the fractionation. (c) The presence of cytosolic cyto c was determined using an antibody directed against cyto c. The results in b and c are representative blots from three different experiments.
Leukemia staining with anti-Bcl-XL. No staining with anti-Bcl-XL was observed in HL-60 cells. Western blot analysis of cytosolic (S100) and mitochondrial (P13) fractions of HL-60 and HL-60/Dox cells were thus done to determine the subcellular localization of Bcl-2, Bcl-XL and Bax. The results illustrated in Figure 5b show that Bax was present at equivalent amounts in both the S100 and P13 in HL-60 and in HL-60/Dox cells. However, Bcl-2 was detected only in the P13 in HL-60 cells while Bcl-XL was present both in the P13 and the S100 in HL-60/Dox cells. Cyto c is one of the components of the caspase-3 activating complex called the apoptosome and is specifically released upon the induction of apoptosis. 15, 16 Western blot analyses were done on cytosolic fractions from control HL-60, apoptotic HL-60 and HL-60/Dox cells. The results depicted in Figure 5c demonstrate the complete absence of cyto c in control HL-60 cytosols. The induction of apoptosis in these cells with STS caused the release of cyto c into the cytosols, shown by the band at 13 kDa. Interestingly, a band at 13 kDa was also observed in untreated HL-60/Dox cytosols.
Absence of cleavage of procaspase-3 and induction of XIAP in HL-60/Dox cells
Procapase-3 is activated into active caspase-3 upon the formation of apoptosome. 15 This maturation was visualized by Western blots then quantifying the diminution of the proform of caspase-3. Analyses of procaspase processing were done using control and apoptotic cell extracts after STS treatment. The results in Figure 6a show that in untreated HL-60 cells procaspase-3 was present as the 32 kDa inactive proenzyme. The intensity of this band diminished with time until 4 h after treatment with STS, which corresponded to the data obtained in the DEVDase assay (Figure 3c ), a result compatible with the 32 kDa procaspase-3 being matured into the 17 and 11 kDa active protein. 20 In HL-60/Dox cells, the 32 kDa band was present at all times and at the same intensity confirming that procaspase-3 was not activated in these cells under STS treatment. Similar results were obtained in the presence of verapamil suggesting that a functional P-gp was not required in this process (data not shown).
To determine whether it was nonetheless possible to acti- vate caspase-3 in HL-60/Dox cells, 250 g S100 HL-60 or HL-60/Dox cells were incubated in the presence of cyto c and dATP, then the DEVDase (Ac-DEVD-AMC substrate for caspase-3), LEHDase (Ac-LEHD-AMC substrate for caspase-9) or VGRase (Bz-VGR-AMC substrate for chymotrypsin) activities were determined. The results in Figure 5b show that both DEVDase and LEHDase activities were detected in both HL-60 and to a lesser degree in HL-60/Dox cytosolic extracts, inferring that it was possible to form the apoptosome and activate caspase-9 which in turn would cleave caspase-3 under cell-free conditions. The VGRase activities were similar in both cell types suggesting that the DEVDase and LEHDase activities assayed were specifically induced by the treatment (data not shown).
The next question was why STS treatment failed to activate procaspase-3? In an attempt to answer this, different concentrations of S100 from HL-60 and HL-60/Dox cells were incubated with cyto c and dATP to activate procaspase-3. The data in Figure 6b illustrate that at low concentrations of S100, no caspase-3 activation was detected in HL-60/Dox while in HL-60, as little as 100 g S100 was required to produce a specific DEVDase activity. Even at the higher concentrations of S100, the specific DEVDase activity measured in HL-60/Dox extracts was always lower than that measured in HL-60 extracts (Figure 7a ). This result is consistent with the presence of a competitive inhibitor in these extracts.
XIAP has been shown to inhibit caspase-3 by binding to the prodomain form thereby preventing the activation of procas-
Figure 7
Activation of caspases in HL-60 and HL-60/Dox S100. pase-3 by apoptosome with cyto c and APAF-1. 29 By Western blotting using an antibody directed against XIAP, a band with an apparent molecular weight of 48 kDa was detected in HL-60/Dox cells only (Figure 7b ). These data are consistent with the fact that the lack of caspase-3 activity in HL-60/Dox cells was probably due to the presence of the XIAP.
Discussion
Many cancers including AML, acute lymphoid leukemia, lymphomas, breast and ovarian cancers express relatively low levels of P-gp at diagnosis, however, with treatment the expression may increase at the time of relapse. 37 A study by Nussler et al 38 showed that while the percentage of P-gp-positive patients increased between the initial diagnosis and relapse, this result had no effect on overall survival. It is possible that other cellular factors in addition to or complementary to P-gp may contribute to the MDR phenotype. A probable explication for this could be the acquisition of additional MDR mechanisms in late relapse.
The primary aim of our study was to analyze acquired chemoresistance. The secondary aim, although no data were presented, was in the acquisition of which chemoresistance arrived first, the proximal arm represented by the expression of P-gp or the distal branch, represented by the expression of members of the family of BCL-2. There have been numerous reports in the literature which have described either one or both but none which analyzed the earliest steps in this acquisition of chemoresistance. In our cells it would appear that the two mechanisms arrived together (data not shown) and not sequentially suggesting that the induction of chemoresistance resulted from multiple changes at the genomic level. A role for P-gp in the elimination of the cytotoxic drugs has been well-established, however, recently, a role for P-gp in the regulation of apoptosis and cell differentiation has been suggested. 35 The latter postulation was made by Chaundary and Robinson 39 who showed that endogenous P-gp expression was down-regulated during differentiation of pluripotent stem cells along the myeloid lineage.
Recent data on apoptosis regulation in mammalian cells suggest that pro-apoptotic Bcl-2 and Bcl-XL could regulate apoptosis by different mechanisms. [24] [25] [26] Using a murine B cell line it was shown that apoptosis induced by immunosuppressants or by the protein synthesis inhibitors could be blocked by Bcl-XL but not by Bcl-2. 40 Also in murine liver, Bcl-XL and not Bcl-2 was shown to block TNF-␣-induced apoptosis. 41 In addition, bcl-2 knockout mice fail to maintain a stable immune system after birth, develop polycystic kidney and have hypopigmented hair but are otherwise normal. 42 In contrast, bcl-XL knockout mice die at embryonic day 13, with apoptosis occurring in hematopoietic and neuronal tissues. 43 These studies clearly point out that Bcl-2 and Bcl-XL could regulate apoptosis differently. One possible reason for the switch in the expression of Bcl-2 to Bcl-XL may be that Bcl-XL could be more protective than Bcl-2. A study by Pallis et al 28 using blast cells from patients with poor prognostic forms of AML, found an association of autonomous growth with coexpression of P-gp and an expression of significantly higher levels of Bcl-XL. In addition, the transfection of murine prolymphocytic cell-line FL5.12 with Bcl-XL has been shown to confer a MDR phenotype. 12 Mcl-1 has been found to be similar to Bcl-2, in that Mcl-1 can promote survival in a variety of cell types under different stimuli conducive to apoptosis. 36 Overexpression of Mcl-1 has been shown to augment the inhiLeukemia bition to apoptosis, induced by different treatments, including UV irradiation. 36 More importantly, a recent study by Kaufmann et al 44 demonstrated that Mcl-1 was increased at the time of leukemic relapse, which reinforces our data suggesting that Mcl-1 may be an important element involved in the selection of resistant clones during chemotherapy. Interestingly, these same authors also observed no corresponding compensatory increase in Bax.
Numerous recent reports have implicated mitochondria in the apoptotic cascade. 15 In agreement with the pivotal role of mitochondria in cell death, is the release of cyto c from the mitochondria and the finding that cyto c itself can induce the activation of caspases. 19 These findings imply a sequential order of events leading to programmed cell death and also suggest a number of distinct levels of the apoptotic pathway which might be subject to regulation.
The data of Duckett et al 32 that Bcl-XL and XIAP have differential effects on cyto c release and cyto c-mediated apoptosis support this hypothesis. That the latter protein is absent in the parental HL-60 cells and overexpressed in HL-60/Dox cells suggests that this protein represents another factor which could regulate the apoptotic pathway, and thus directly or indirectly chemoresistance. The presence of cytosolic cyto c in HL 60/Dox cells is quite striking, since the release of cyto c from mitochondria has been implied to be the point of no return in apoptosis. However, recent data have suggested that prevention of caspase activation or their inhibition extend cell life beyond the release of cyto c providing that mitochondrial physiology was not affected. 45 In HL60/DOX cells the increased expression of XIAP could be responsible of the lack of activation of caspases but one can postulate that the main determinant for HL60/DOX survival, is the mitochondrial adaptation to the leakage of cyto c. Such postmitochondrial regulation of apoptosis at the level of caspase activation has already been discribed with inhibitors of caspases, including the human IAP-like proteins. 46 The precise mechanism of 'mitochondrial resistance' is currently under investigation in our laboratory.
We hypothesize that the switch in the expression from Bcl-2 to Bcl-XL rendered the cells more resistant to cell death because the subcellular localization of Bcl-XL being both cytosolic and mitochondrial facilitated the prevention of the formation of the apoptosome by the binding of Bcl-XL to Apaf-1. 47, 48 The inhibition of the activation of the procaspase-3 was further ensured by the presence of XIAP which directly inhibited the proteolytic activation of caspase-3. The latter results illustrate the fact that, contrary to what has been suggested, the release of cyto c is not the point of no return of the execution phase of apoptosis. 49 A large part of our data demonstrates that the induction of P-gp was not the only form of resistance acquired; this inability of HL-60/Dox cells to undergo apoptosis even in the presence of verapamil, a pharmacological inhibitor of P-gp function. As discussed above, the addition of P-gp modulators had, in general, no effect on overall survival reinforcing the idea that chemoresistance could have multiple causes. Our results appear, however, to be in direct conflict with those of the group of Johnstone, 8 who showed that by blocking P-gp with verapamil the chemoresistance observed in their cells were reversed. One possible explanation for this discrepancy could be that the cells used in the latter study had only one form of chemoresistance, ie the expression of P-gp and none of the other possible chemoresistant parameters. This is emphasized by the fact that half of the P-gp-positive cell lines used were transfected and gave similar results as the druginduced cell lines.
In conclusion, our data suggest that it is not sufficient to determine chemoresistance by analyzing the expression of Pgp but a more complete analysis would be required involving all levels of the apoptotic pathway.
